University of Colorado Cancer Center | Strategic Alliance Partners

Latest from University of Colorado Cancer Center


Published Entrectinib Data Demonstrate Encouraging Responses in ROS1+ NSCLC

December 16, 2019

Treatment with entrectinib led to an overall response rate of 77% and a median duration of response of 24.6 months in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated findings of a pooled analysis published in Lancet Oncology.

x